Engrail
Engrail Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 and focused on precision neuroscience. The company develops innovative, precision-targeted small-molecule therapeutics aimed at the molecular mechanisms and neural circuits underlying nervous system disorders, combining internal discovery with strategic partnerships. Its pipeline includes candidates ENX-102, ENX-104, ENX-203, and ENX-205 for patients with devastating and life-limiting neurological conditions. Surfaced as a portfolio company of Norwest Venture Partners and profiled in the API Evangelist network; the company publishes no public developer/API surface.
Engrail is profiled on the APIs.io network. Tagged areas include Company, Pharmaceutical, Biotechnology, Neuroscience, and Drug Development.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API